IL290212A - Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazole-5-carboxamide] derivatives and related compounds as sting (interferon gene stimulator) agonists for cancer therapy - Google Patents
Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazole-5-carboxamide] derivatives and related compounds as sting (interferon gene stimulator) agonists for cancer therapyInfo
- Publication number
- IL290212A IL290212A IL290212A IL29021222A IL290212A IL 290212 A IL290212 A IL 290212A IL 290212 A IL290212 A IL 290212A IL 29021222 A IL29021222 A IL 29021222A IL 290212 A IL290212 A IL 290212A
- Authority
- IL
- Israel
- Prior art keywords
- sting
- stimulator
- pyrazol
- imidazol
- carboxamide
- Prior art date
Links
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882081P | 2019-08-02 | 2019-08-02 | |
| US201962944643P | 2019-12-06 | 2019-12-06 | |
| US202062982935P | 2020-02-28 | 2020-02-28 | |
| PCT/US2020/044538 WO2021026009A1 (en) | 2019-08-02 | 2020-07-31 | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290212A true IL290212A (en) | 2022-03-01 |
Family
ID=72179195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290212A IL290212A (en) | 2019-08-02 | 2022-01-30 | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazole-5-carboxamide] derivatives and related compounds as sting (interferon gene stimulator) agonists for cancer therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11155567B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4007758B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7843695B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220056176A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114585623A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020324388B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001931A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3149482A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4007758T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4007758T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290212A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022001407A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202120500A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021026009A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202201505B (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| JP7664680B2 (ja) | 2017-03-29 | 2025-04-18 | リガケム バイオサイエンシズ, インク. | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物 |
| KR102702618B1 (ko) * | 2019-01-31 | 2024-09-06 | 히트젠 주식회사 | 면역조절제 |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| WO2022177307A1 (ko) * | 2021-02-17 | 2022-08-25 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| CN116940574B (zh) * | 2021-05-24 | 2026-05-05 | 复旦大学 | 化合物及其作为疫苗佐剂的用途 |
| CN114948955A (zh) * | 2022-06-06 | 2022-08-30 | 中国科学技术大学 | 靶向环鸟苷酸-腺苷酸合成酶的小分子共价抑制剂及其用途 |
| KR20250120285A (ko) * | 2022-11-08 | 2025-08-08 | 주식회사 리가켐바이오사이언스 | Sting 작용제 |
| WO2024174863A1 (zh) * | 2023-02-22 | 2024-08-29 | 深圳众格生物科技有限公司 | Sting激动剂及其制备方法和医药用途 |
| WO2024182414A1 (en) * | 2023-02-27 | 2024-09-06 | Biontech Us Inc. | Sting agonists containing hydrazide, hydrazine, and hydroxamic acid functional groups |
| WO2024186626A1 (en) * | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2024192017A1 (en) | 2023-03-13 | 2024-09-19 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists, combinations and methods of use |
| AU2024315750A1 (en) | 2023-07-31 | 2026-03-05 | Sutro Biopharma, Inc. | Sting agonist compounds and conjugates |
| CN117229310B (zh) * | 2023-09-18 | 2026-03-31 | 上海皓元生物医药科技有限公司 | 一种sting激动剂及其中间体的制备方法 |
| TW202613130A (zh) | 2024-05-30 | 2026-04-01 | 日商安斯泰來製藥股份有限公司 | Sting促效劑免疫刺激性抗體藥物結合物 |
| USD1125537S1 (en) * | 2024-08-26 | 2026-05-05 | Astrazeneca Ab | Medical injector |
| WO2026078593A1 (en) | 2024-10-08 | 2026-04-16 | Sun Pharma Advanced Research Company Limited | Sting agonists and antibody drug conjugates thereof |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AU2002234755A1 (en) | 2001-02-26 | 2002-09-12 | Pharma Pacific Pty Ltd | Interferon-alpha induced gene |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| EP2250201B1 (en) | 2008-01-29 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| KR20180066241A (ko) | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingの調節因子としての環状プリンジヌクレオチド |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) * | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| JP6636673B2 (ja) | 2016-10-04 | 2020-01-29 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | STINGアゴニストとしてのベンゾ[b]チオフェン化合物 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| WO2018227023A1 (en) | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| EP3685166A2 (en) | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| CA3078309A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Methods for administering sting agonists |
| US11377440B2 (en) * | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CA3247730A1 (en) | 2017-11-07 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| CN110016021B (zh) | 2018-01-08 | 2021-05-07 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN110016025B (zh) | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| EP3802534B1 (en) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| US20210353652A1 (en) | 2018-06-04 | 2021-11-18 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
| WO2019243825A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Small molecule modulators of human sting, conjugates and therapeutic applications |
| CN112351778B (zh) | 2018-06-28 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 稠合三环杂环类化合物及其治疗用途 |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| AU2019326633B2 (en) | 2018-08-24 | 2022-09-08 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| CA3110474C (en) | 2018-08-29 | 2024-04-23 | Adlai Nortye Biopharma Co., Ltd. | Highly active sting protein agonist compound |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| CN110963997A (zh) | 2018-09-28 | 2020-04-07 | 四川科伦博泰生物医药股份有限公司 | 杂环酰胺类化合物、包含其的药物组合物及其制备方法和用途 |
| WO2020115676A1 (en) * | 2018-12-06 | 2020-06-11 | Glaxosmithkline Intellectual Property Development Limited | Novel pharmaceutical formulation |
| WO2020132566A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting pyrazole agonists and uses thereof |
| WO2020132549A1 (en) | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting heterocycle agonists and uses thereof |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| CN111393404B (zh) | 2019-01-02 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯并噻吩类化合物及其药物组合物及应用 |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| CN111471056B (zh) | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| KR102702618B1 (ko) | 2019-01-31 | 2024-09-06 | 히트젠 주식회사 | 면역조절제 |
| WO2020181050A1 (en) | 2019-03-05 | 2020-09-10 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| KR20210146370A (ko) | 2019-03-28 | 2021-12-03 | 루핀 리미티드 | Sting 효능제로서의 매크로사이클릭 화합물 |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| JP2022529183A (ja) | 2019-04-17 | 2022-06-17 | アヴィディア テクノロジーズ, インコーポレイテッド | リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法 |
| CN111848573B (zh) | 2019-04-30 | 2023-04-07 | 四川科伦博泰生物医药股份有限公司 | 苯并噻吩酰胺类化合物及其制备方法和用途 |
| JP7531508B2 (ja) | 2019-04-30 | 2024-08-09 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | ベンゾチオフェン化合物、その調製方法およびその使用 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| WO2021000770A1 (zh) | 2019-07-02 | 2021-01-07 | 凯复制药有限公司 | 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| DK4004002T3 (da) | 2019-07-22 | 2024-09-30 | Lupin Ltd | Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed |
| CN112300227B (zh) | 2019-07-25 | 2023-11-28 | 江西济民可信集团有限公司 | 杂环酰胺类化合物及其制备方法和应用 |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| US20230074558A1 (en) | 2019-12-06 | 2023-03-09 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
| CN113248475B (zh) | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| CN112898286A (zh) | 2021-01-28 | 2021-06-04 | 中国药科大学 | 苯并噻吩类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途 |
-
2020
- 2020-07-31 KR KR1020227005762A patent/KR20220056176A/ko not_active Ceased
- 2020-07-31 US US16/944,646 patent/US11155567B2/en active Active
- 2020-07-31 EP EP20760644.3A patent/EP4007758B1/en active Active
- 2020-07-31 MX MX2022001407A patent/MX2022001407A/es unknown
- 2020-07-31 AU AU2020324388A patent/AU2020324388B2/en active Active
- 2020-07-31 DK DK20760644.3T patent/DK4007758T3/da active
- 2020-07-31 FI FIEP20760644.3T patent/FI4007758T3/fi active
- 2020-07-31 WO PCT/US2020/044538 patent/WO2021026009A1/en not_active Ceased
- 2020-07-31 JP JP2022506588A patent/JP7843695B2/ja active Active
- 2020-07-31 TW TW109126070A patent/TW202120500A/zh unknown
- 2020-07-31 CN CN202080070155.6A patent/CN114585623A/zh active Pending
- 2020-07-31 BR BR112022001931A patent/BR112022001931A2/pt unknown
- 2020-07-31 CA CA3149482A patent/CA3149482A1/en active Pending
-
2021
- 2021-09-09 US US17/469,983 patent/US11939343B2/en active Active
-
2022
- 2022-01-30 IL IL290212A patent/IL290212A/en unknown
- 2022-02-01 MX MX2025006327A patent/MX2025006327A/es unknown
- 2022-02-02 ZA ZA2022/01505A patent/ZA202201505B/en unknown
-
2024
- 2024-02-05 US US18/432,751 patent/US20250011339A1/en active Pending
-
2026
- 2026-03-31 JP JP2026057935A patent/JP2026116989A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025006327A (es) | 2025-07-01 |
| EP4007758A1 (en) | 2022-06-08 |
| WO2021026009A1 (en) | 2021-02-11 |
| AU2020324388A1 (en) | 2022-02-24 |
| JP7843695B2 (ja) | 2026-04-10 |
| US20250011339A1 (en) | 2025-01-09 |
| JP2026116989A (ja) | 2026-07-14 |
| EP4007758B1 (en) | 2026-05-13 |
| US20210032269A1 (en) | 2021-02-04 |
| US11939343B2 (en) | 2024-03-26 |
| JP2022543086A (ja) | 2022-10-07 |
| CN114585623A (zh) | 2022-06-03 |
| AU2020324388B2 (en) | 2026-07-16 |
| US11155567B2 (en) | 2021-10-26 |
| FI4007758T3 (fi) | 2026-08-04 |
| US20220064189A1 (en) | 2022-03-03 |
| DK4007758T3 (da) | 2026-08-03 |
| CA3149482A1 (en) | 2021-02-11 |
| KR20220056176A (ko) | 2022-05-04 |
| MX2022001407A (es) | 2022-04-27 |
| TW202120500A (zh) | 2021-06-01 |
| ZA202201505B (en) | 2024-07-31 |
| BR112022001931A2 (pt) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ745957A (en) | Heterocyclic amides useful as protein modulators | |
| IL288104B1 (en) | Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer | |
| ZA202201505B (en) | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer | |
| IL278178A (en) | Use of pilocarpine hydrochloride to treat eye disorder | |
| EP3873335A4 (en) | CHARACTERIZATION OF THERAPEUTIC EFFECTIVENESS OF NEUROSTIMULATION | |
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| PH12018500792A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
| PH12021551290A1 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| PT3805233T (pt) | Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| CY1126039T1 (el) | Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm | |
| EP3950686A4 (en) | N-HETEROAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | |
| MX2009004791A (es) | Derivados de anilinopiperazina t metodos de uso de los mismos. | |
| MX2009004785A (es) | Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa. | |
| MX2010004878A (es) | Derivados de tioeter y eter heterociclico y metodos de uso de los mismos. | |
| MX2010004875A (es) | Derivados de tiazol y metodos para utilizarlos. | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| MX382436B (es) | Derivados de quinolin-2-ona. | |
| IL292657A (en) | Therapeutic history of interleukin-22 | |
| MX2010004880A (es) | Derivados heterociclicos de urea y tiourea, y metodos de uso de los mismos. | |
| IL299206A (en) | Methods for treating cancer using heteroaryl-biphenyl amide derivatives | |
| KR102462548B9 (ko) | CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| SMT202500123T1 (it) | Composti eterociclici per uso nel trattamento del cancro | |
| EP3347010A4 (en) | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | |
| MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. |